Review ArticleBiomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Keywords
Cited by (0)
Disclosure: Dr. Peled is an advisor for and has received honoraria from AstraZemeca, Bohringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, NovellusDx, Foundation Medicine, Inc., and Gaurdant360; in addition, he is a coinventor in breath analysis in lung cancer. Dr. Ajona, Dr. Pio, and Dr. Montuenga are listed as coinventors of two patents related to the use of complement fragments as biomarkers. Dr. Sozzi and Dr. Boeri are coinventors of three patent applications regarding the microRNA signature MSC. These patents were licensed to a private company, Gensignia Life Science, under regulations of Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. Dr. Zulueta is an employee and shareholder of VisionGate, Inc. Dr. Spira is an employee of Johnson and Johnson and has provided prior consultant to Veracyte, Inc. Dr. Mazzone has participated in advisory board discussions for Exact Sciences, SeerPharma, and Grail in the past 12 months. Dr. Seijo has received professional fees for speaking engagements regarding lung cancer screening and received an unrestricted grant from Menarini in support of the Jimenez Díaz Foundation’s lung cancer screening program. The remaining authors declare no conflict of interest.